12.70
0.79%
+0.10
Cidara Therapeutics Inc (CDTX) 最新ニュース
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
GlobeNewswire Inc.
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
GlobeNewswire Inc.
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
GlobeNewswire Inc.
Cidara Therapeutics Announces Reverse Stock Split
GlobeNewswire Inc.
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
GlobeNewswire Inc.
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
Zacks Investment Research
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
GlobeNewswire Inc.
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
Zacks Investment Research
Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
GlobeNewswire Inc.
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
GlobeNewswire Inc.
大文字化:
|
ボリューム (24 時間):